Literature DB >> 23237317

Contribution of common genetic variants to antidepressant response.

Katherine E Tansey1, Michel Guipponi, Xiaolan Hu, Enrico Domenici, Glyn Lewis, Alain Malafosse, Jens R Wendland, Cathryn M Lewis, Peter McGuffin, Rudolf Uher.   

Abstract

BACKGROUND: Pharmacogenetic studies aiming to personalize the treatment of depression are based on the assumption that response to antidepressants is a heritable trait, but there is no compelling evidence to support this.
METHODS: We estimate the contribution of common genetic variation to antidepressant response with Genome-Wide Complex Trait Analysis in a combined sample of 2799 antidepressant-treated subjects with major depressive disorder and genome-wide genotype data.
RESULTS: We find that common genetic variants explain 42% (SE = .180, p = .009) of individual differences in antidepressant response.
CONCLUSIONS: These results suggest that response to antidepressants is a complex trait with substantial contribution from a large number of common genetic variants of small effect.
Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23237317     DOI: 10.1016/j.biopsych.2012.10.030

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  65 in total

Review 1.  Moving pharmacoepigenetics tools for depression toward clinical use.

Authors:  Laura M Hack; Gabriel R Fries; Harris A Eyre; Chad A Bousman; Ajeet B Singh; Joao Quevedo; Vineeth P John; Bernhard T Baune; Boadie W Dunlop
Journal:  J Affect Disord       Date:  2019-02-06       Impact factor: 4.839

Review 2.  Toward a Global Roadmap for Precision Medicine in Psychiatry: Challenges and Opportunities.

Authors:  Shareefa Dalvie; Nastassja Koen; Nathaniel McGregor; Kevin O'Connell; Louise Warnich; Raj Ramesar; Caroline M Nievergelt; Dan J Stein
Journal:  OMICS       Date:  2016-09-16

Review 3.  Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.

Authors:  Chiara Fabbri; Alessandro Serretti
Journal:  Curr Psychiatry Rep       Date:  2015-07       Impact factor: 5.285

Review 4.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

5.  A Preliminary Study of Genetic Variation in the Dopaminergic and Serotonergic Systems and Genome-wide Additive Genetic Effects on Depression Severity and Treatment Response.

Authors:  Rohan H C Palmer; Christopher G Beevers; John E McGeary; Leslie A Brick; Valerie S Knopik
Journal:  Clin Psychol Sci       Date:  2016-10-19

Review 6.  Identifying genetic loci affecting antidepressant drug response in depression using drug-gene interaction models.

Authors:  Raymond Noordam; Christy L Avery; Loes E Visser; Bruno H Stricker
Journal:  Pharmacogenomics       Date:  2016-06-01       Impact factor: 2.533

Review 7.  Psychiatric genetics and the future of personalized treatment.

Authors:  Jordan W Smoller
Journal:  Depress Anxiety       Date:  2014-11       Impact factor: 6.505

8.  Neuronal cell adhesion genes and antidepressant response in three independent samples.

Authors:  C Fabbri; C Crisafulli; D Gurwitz; J Stingl; R Calati; D Albani; G Forloni; M Calabrò; R Martines; S Kasper; J Zohar; A Juven-Wetzler; D Souery; S Montgomery; J Mendlewicz; G D Girolamo; A Serretti
Journal:  Pharmacogenomics J       Date:  2015-04-07       Impact factor: 3.550

Review 9.  Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2017-04-11

10.  Patient characteristics driving clinical utility in psychiatric pharmacogenetics: a reanalysis from the AB-GEN multicentric trial.

Authors:  J M Menchón; J Espadaler; M Tuson; J Saiz-Ruiz; J Bobes; E Vieta; E Álvarez; V Pérez
Journal:  J Neural Transm (Vienna)       Date:  2018-05-04       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.